The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | PACIFICA: Phase III study of pacritinib vs BAT in patients with MF and severe thrombocytopenia
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, describes the design of the ongoing Phase III PACIFICA trial (NCT03165734), which aims to confirm efficacy and safety of pacritinib versus best available therapy (BAT) in patients with myelofibrosis (MF) and severe thrombocytopenia. Prof. Harrison explains that recent studies have demonstrated that similarly to momelotinib, pacritinib targets ACVR1, which translates to a transfusion benefit. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Geron: Membership on an entity’s Board of Directors or advisory committees; Keros: Consultancy; Constellation Pharmaceuticals, Inc., a MorphoSys Company: Membership on an entity’s Board of Directors or advisory committees, Research Funding; EHA: Other: Leadership role; MPN voice: Other: Leadership role; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Shire: Membership on an entity’s Board of Directors or advisory committees; Sierra: Honoraria; AOP Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Promedior: Membership on an entity’s Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Janssen: Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees; Galecto: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees, Other: Support for attending meetings, Research Funding; Galacteo: Membership on an entity’s Board of Directors or advisory committees; Celgene/BMS: Membership on an entity’s Board of Directors or advisory committees, Research Funding.
